Stock Track | Xeris Pharmaceuticals (XERS) Soars 5.16% Pre-market on Record Q4 Results, Strong 2025 Outlook

Stock Track
03-06

Shares of Xeris Pharmaceuticals Inc (NASDAQ: XERS) rallied 5.16% in pre-market trading on Thursday, following the company's outstanding fourth quarter and full-year 2024 financial results, along with upbeat revenue guidance for 2025.

For the fourth quarter, Xeris reported record total revenue of $60.1 million, up 35.4% year-over-year, driven by strong sales growth of its key products Gvoke and Recorlev. Net revenue for Gvoke, the company's ready-to-use liquid glucagon for severe hypoglycemia, rose 24.8% to $23.3 million, while Recorlev, a treatment for endogenous Cushing's syndrome, more than doubled its revenue to $22.6 million, reflecting a 130.6% increase.

The robust quarterly performance translated into a record full-year 2024 revenue of $203.1 million, up 23.9% compared to the prior year. Gvoke and Recorlev continued their momentum throughout the year, with revenue growth of 23.5% and 117.5%, respectively.

Furthermore, Xeris achieved positive cash flow and Adjusted EBITDA of $8.3 million in the fourth quarter, highlighting the company's improving financial position and operational efficiency.

Looking ahead, Xeris provided an optimistic revenue guidance for 2025, projecting total revenue in the range of $255 million to $275 million, representing growth of over 30% at the mid-point of the range. This strong outlook reflects the company's confidence in continued market share gains and expanding demand for its innovative product portfolio.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10